JP7434276B2 - Icam-1アプタマー、その診断および治療用途 - Google Patents
Icam-1アプタマー、その診断および治療用途 Download PDFInfo
- Publication number
- JP7434276B2 JP7434276B2 JP2021504188A JP2021504188A JP7434276B2 JP 7434276 B2 JP7434276 B2 JP 7434276B2 JP 2021504188 A JP2021504188 A JP 2021504188A JP 2021504188 A JP2021504188 A JP 2021504188A JP 7434276 B2 JP7434276 B2 JP 7434276B2
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- icam
- moiety
- imaging
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091023037 Aptamer Proteins 0.000 title claims description 82
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 title claims description 51
- 230000001225 therapeutic effect Effects 0.000 title claims description 6
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 title description 46
- 238000003384 imaging method Methods 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000012986 modification Methods 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 238000002591 computed tomography Methods 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 238000010494 dissociation reaction Methods 0.000 claims description 6
- 230000005593 dissociations Effects 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- 230000021615 conjugation Effects 0.000 claims description 4
- 230000005291 magnetic effect Effects 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 4
- 238000012800 visualization Methods 0.000 claims description 4
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 230000003511 endothelial effect Effects 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 210000004789 organ system Anatomy 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 238000007385 chemical modification Methods 0.000 claims description 2
- 238000002372 labelling Methods 0.000 claims description 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 230000005298 paramagnetic effect Effects 0.000 claims description 2
- 238000002600 positron emission tomography Methods 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 6
- 239000007801 affinity label Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000003325 tomography Methods 0.000 claims 1
- 238000012285 ultrasound imaging Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 11
- 238000011529 RT qPCR Methods 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 9
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 238000000159 protein binding assay Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241001349468 Elona Species 0.000 description 4
- 108091008103 RNA aptamers Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- -1 VCAM Proteins 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000002961 echo contrast media Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 102000043559 human ICAM1 Human genes 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000010379 pull-down assay Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 108010059108 CD18 Antigens Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101150050263 ICAM1 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000001386 capillary affinity electrophoresis Methods 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000002607 contrast-enhanced ultrasound Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 241000264288 mixed libraries Species 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002101 nanobubble Substances 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 108010051423 streptavidin-agarose Proteins 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
Description
アプタマー
最近、アプタマーと呼ばれる機能的なオリゴヌクレオチドベースの生体分子が、抗体の有望な代替物として大きな関心を集めている。アプタマー選択の技術は、病気の診断と治療に応用できるため科学界において注目されている。
細胞間接着分子(ICAM)は、免疫グロブリンスーパージーンファミリーの構造的に関連する膜貫通糖タンパク質であり、白血球に存在するβ2インテグリン分子のリガンドである(Almenar-Queralt A. et al., Am. J. Pathol., 1995, 147(5), 1278-1288; Hubbard AK et al, Free Radic. Biol. Med., 2000, 28, 1379-1386)。同定された5つのICAMのうち、ICAM-1が最もよく研究されている(Koning et al., Endothelium, 2002, 9, 161-171; Muro et al., Curr. Pharm. Des., 2005, 11, 2383-2401)。ICAM-1(細胞間接着分子1)は、ヒトにおいてICAM1遺伝子によってコードされるタンパク質である。この遺伝子は、通常、内皮細胞および免疫系の細胞上に発現する細胞表面をコードする。ICAM-1は、CD11a/CD18型またはCD11b/CD18型のインテグリンに結合し、受容体としてライノウイルスに利用される。
本発明は、ICAM-1分子に高い親和性で結合することができるRNAアプタマーの同定に基づく。特に、本発明のアプタマーは、それが生理学的に存在する部位、すなわち、ICAM-1が発現する細胞表面上で標的を特異的に認識するという課題を解決し、in vivoでそれらの使用に適していることを実証する。実際、本明細書に記載のアプタマーは、表面でICAM-1を過剰発現している細胞に直接結合できることが見出された。
UCAUGAUACGUUGCGUGAGCAACUGCGGCGCUAAAGUUUGGUUGACUAGUACAUG(配列番号1)はICAM-1に対して最も高い結合親和性を示した。
GGGAAGAGAAGGACAUAUGAUCAUGAUACGUUGCGUGAGCAACUGCGGCGCUAAAGUUUGGUUGACUAGUACAUGACCACUUGA (配列番号2)
は、同様にICAM-1に結合することができることが示された。
本発明のアプタマーは、例えば、ヌクレアーゼに対する耐性を高めるため、薬物動態を調節するため、または診断部分または治療部分とコンジュゲートさせるために修飾することができる。
配列番号1は、アプタマー10.T(55nt)の5’からの配列を示している。
5’ UCAUGAUACGUUGCGUGAGCAACUGCGGCGCUAAAGUUUGGUUGACUAG
UACAUG 3’
配列番号2は、アプタマー12c-10(84nt)の5’からの配列を示している。
5’ GGGAAGAGAAGGACAUAUGAUCAUGAUACGUUGCGUGAGCAACUGCGGCG
CUAAAGUUUGGUUGACUAGUACAUGACCACU UGA 3’
装置
フローサイトメトリーデータの取得は、BD AccuriTM C6フローサイトメーター(BD Bioscience)を使用して行った。RT-qPCRは、StepOneTM PlusリアルタイムPCRシステム(Applied Biosystems)により行った。ゲルの可視化は、Gel Doc EZ System(Bio-Rad)を用いて行った。ELONAデータは、MultiskanTM FCマイクロプレート光度計(ThermoFisher Scientific)によって取得した。
ICAM-1 細胞間接着分子-1
SELEX Systematic Evolution of Ligands by Exponential enrichment
RNA リボ核酸
DNA デオキシリボ核酸
WT 野生型
nt ヌクレオチド
HSA ヒト血清アルブミン
KD 解離定数
HMEC-1 ヒト乳腺上皮細胞-1
TNFalpha 腫瘍壊死因子アルファ
COS7 SV40遺伝物質を有するCV-1(サル)を起源とする細胞
Rt-qPCR リアルタイムポリメラーゼ連鎖反応
ICAM-1に対するアプタマーを特異的に選択するため、細胞表面に存在する他のタンパク質について異なる2つの細胞株(陽性/陰性)の代わりに、同じ細胞株(過剰発現した標的あり/なし)を用いて、cell-SELEX法に従い行った。
短いアプタマー10.T(配列番号1)が、元の分子である12C-10(配列番号2)の活性部位を含み、COS7-ICAM-1に対する高い結合と親和性を保存しているかを試験する目的で、長いアプタマーのスクリーニングに使用したのと同じ条件を維持して結合アッセイを行った。
アプタマー10.Tの結合について別の実験でさらに調べた。5’末端をビオチン化したアプタマー10.Tについてプルダウンアッセイを行い、その配列が、標的であるICAM-1に結合することを確認した。COS7細胞をICAM-1 cDNAで48時間一過性トランスフェクトして回収し、リゼート300μgを、1μMのビオチン化アプタマー10.T、およびネガティブコントロールとして使用するICAM-1-非関連2’F-RNA配列とインキュベートした。複合体をストレプトアビジンアガロースビーズと連続してインキュベートした。数回の洗浄と変性の後、図7に示すように、サンプルをイムノブロッティングで分析した。
アプタマー10.Tを、ヒト血清中での安定性について試験した。87%ヒト血清中で37℃にてインキュベートした。サンプルを種々の時間(T0、1、2、4、8、12、24、48、72時間)で採取し、プロテイナーゼKと37℃で1時間インキュベートして血清タンパク質を分解し、変性ゲルにロードした。結果は、アプタマー10.Tの半減期が4~8時間であることを示した。安定性の結果を図6に示す。
イメージング用途における10.Tアプタマー使用の可能性を実証するため、C12-アミノリンカー(5’-C12-NH2)を挿入した後、RNA配列の5’末端を市販の色素Alexa Fluor488に結合させた。アミノリンカーは、塩基的触媒作用によりC12脂肪族ジアミンとの縮合により5’末端リン酸に挿入した。得られたフリーのNH2部分を、市販のAlexa Fluor 488-NHSエステルと反応させて共有結合によりアミド結合を形成した。Alexa Fluor 488-NHSエステルを高純度の無水ジメチルホルムアミド(DMF)またはジメチルスルホキシド(DMSO)に溶解し、0.1~0.2M炭酸水素ナトリウム緩衝液(pH 8.3)中で室温にて反応させた。精製を、PAGE、続いてHPLCにより実施した。
標的に対する親和性を調べるため、アプタマー10.Tを、酵母tRNA 200μg/mLで前処理した後、濃度を上げながら(10-50-100-250-500-1000nM)COS7-ICAM-1細胞上で37℃にて15分間インキュベートした。同じ実験を、ネガティブコントロールとして非関連アプタマーA10(配列はLupold S.E. et al., Cancer Res. 2002, 62, 4029-4033に開示)を用いて行った。結合をRT-qPCRによって評価した。図8に示されるようにKd値は375.7±151.7nMであった。
ヒト血清アルブミン(HSA)のKd値を計算するため、ELONAアッセイを行った。ビオチン化アプタマー10.Tを、HSA 25nMで事前にコーティングしたまたはコーティングされていない96ウェルマイクロタイター高結合プレート上で、濃度を上げながら(1-10-100-1000nM)インキュベートした。Kd値は計算できず、10.Tは1000nM以下ではHSAと反応しないことを示した。各実験では、ビオチン化ポリクローナル抗体抗HSAをポジティブコントロールとして使用した。この実験の結果を図11に示す。
Claims (15)
- 配列番号1のRNA配列を含む、細胞間接着分子-1(ICAM-1)に結合するアプタマー。
- 最大100ヌクレオチドの長さを有することを特徴とする、請求項1に記載のアプタマー。
- 500nM~50nMの解離定数でICAM-1に結合することができる、請求項1または2に記載のアプタマー。
- 配列番号2のRNA配列を含む、請求項1~3のいずれかに記載のアプタマー。
- すべてのピリミジン残基が2’-フルオロピリミジンに修飾されている、請求項1~4のいずれかに記載のアプタマー。
- 少なくとも1つの化学修飾を含むようさらなる修飾がされており、該修飾が、糖の位置での化学的置換;リン酸の位置での化学置換;および核酸の塩基の位置での化学置換、から選択される、請求項5に記載のアプタマー。
- 修飾が、修飾ヌクレオチドの組み込み、化合物とのコンジュゲーション、およびレポーター部分による標識からなる群から選択される、請求項6に記載のアプタマー。
- レポーター部分が、フルオロフォア部分、磁性または常磁性部分、放射性標識部分、親和性標識、X線部分、超音波イメージング部分、光音響イメージング部分およびナノ粒子ベース部分からなる群から選択される、請求項7に記載のアプタマー。
- ICAM1関連の病状、障害、機能不全、状態または疾患の診断、治療または視覚化における使用のための、請求項1~8のいずれかに記載のアプタマー。
- ICAM-1関連の病状、障害、機能不全、状態または疾患が、炎症または炎症関連疾患である、請求項9に記載の使用のためのアプタマー。
- 前記診断または視覚化が、ICAM-1を発現する体組織または器官系のイメージングを含んでなる、請求項9に記載の使用のためのアプタマー。
- 前記組織および器官系が、それぞれ内皮および血管である、請求項11に記載の使用のためのアプタマー。
- 薬学的に許容される担体および賦形剤と共に、請求項1~8のいずれかに記載のアプタマーを含有する、診断、治療またはイメージング組成物。
- 器官または組織のイメージングに適している、請求項13に記載の組成物。
- イメージングが、磁気共鳴画像法、陽電子放出断層撮影法(PET)、コンピュータ断層撮影法(CT)、超音波、光音響画像法(PAI)、近赤外蛍光(NIRF)、または単一光子放出コンピュータ断層撮影(SPECT)に基づく、請求項14に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18185794 | 2018-07-26 | ||
EP18185794.7 | 2018-07-26 | ||
PCT/EP2019/069917 WO2020020947A1 (en) | 2018-07-26 | 2019-07-24 | Icam-1 aptamers, diagnostic and therapeutic uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021531020A JP2021531020A (ja) | 2021-11-18 |
JP7434276B2 true JP7434276B2 (ja) | 2024-02-20 |
Family
ID=63077776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021504188A Active JP7434276B2 (ja) | 2018-07-26 | 2019-07-24 | Icam-1アプタマー、その診断および治療用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11274308B2 (ja) |
EP (1) | EP3827082A1 (ja) |
JP (1) | JP7434276B2 (ja) |
CN (1) | CN112469828B (ja) |
WO (1) | WO2020020947A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021086266A1 (en) * | 2019-10-28 | 2021-05-06 | National University Of Singapore | Dnmt1 -specific aptamers and production and uses thereof |
US11859187B2 (en) | 2020-06-25 | 2024-01-02 | The Procter & Gamble Company | Aptamers for personal health care applications |
WO2023114800A1 (en) * | 2021-12-14 | 2023-06-22 | The Procter & Gamble Company | Aptamers for personal health care applications |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105779459A (zh) | 2016-04-10 | 2016-07-20 | 杨岭燕 | 一种用于妇产科中胎膜破裂诊断用的适配子及其试剂盒 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756291A (en) | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
US20050187174A1 (en) * | 2001-05-18 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
US7767803B2 (en) * | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
BRPI0509911A (pt) | 2004-04-13 | 2007-09-18 | Osi Eyetech Inc | método para inibir a atividade de um sìtio separado de um sìtio de ligação de aptámero em um ligando, métodos para aumentar a faixa antagonista, de receptor de um aptámero de ligação de ligando, do ligando de um aptámero de ligação de receptor, de receptor de um aptámero de vegf, e do ligando de um aptámero de vegfr, método para aumentar uma propriedade antagonista de um aptámero que alveja uma proteìna que interage com uma segunda proteìna, método para identificar um conjugado de aptámero, composto, métodos para liberar uma molécula biologicamente ativa, ácido nucléico, um aptámero, e um aptámero anti-vegf a um olho, composto, composição para liberar uma molécula biologicamente ativa a um olho |
US20130209514A1 (en) | 2009-06-09 | 2013-08-15 | Eli Gilboa | Aptamer-targeted costimulatory ligand aptamer |
US20130004490A1 (en) * | 2009-12-14 | 2013-01-03 | The United States of America, as represented by the Secretary, Department | Delivery of transthyretin across the blood-brain barrier as a treatment for alzheimer's disease |
US8623369B2 (en) * | 2010-04-27 | 2014-01-07 | National Research Council Of Canada | Anti-ICAM-1 single domain antibody and uses thereof |
AU2013340414B2 (en) * | 2012-10-23 | 2019-05-02 | Caris Science, Inc. | Aptamers and uses thereof |
EP2976427A4 (en) * | 2013-03-18 | 2017-02-22 | University Of The Witwatersrand, Johannesburg | Cd7 receptor aptamers |
CN104212800B (zh) * | 2013-05-07 | 2017-01-18 | 南方医科大学 | 一种与人表皮生长因子受体iii型突变体特异性结合的核酸适配子及其应用 |
BR112016004153A2 (pt) * | 2013-08-28 | 2019-09-17 | Caris Life Sciences Switzerland Holdings Gmbh | "método para caracterizar uma doença ou distúrbio, kit, composição, método para gerar uma biblioteca de entrada, oligonucleotídeo, pluralidade de oligonucleotídeos e método para identificar um aptâmero |
CN106199008A (zh) * | 2015-11-01 | 2016-12-07 | 李倩 | 一种用于检测眼病的试剂盒及其检测方法 |
-
2019
- 2019-07-24 CN CN201980049353.1A patent/CN112469828B/zh active Active
- 2019-07-24 EP EP19745118.0A patent/EP3827082A1/en active Pending
- 2019-07-24 US US17/262,835 patent/US11274308B2/en active Active
- 2019-07-24 JP JP2021504188A patent/JP7434276B2/ja active Active
- 2019-07-24 WO PCT/EP2019/069917 patent/WO2020020947A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105779459A (zh) | 2016-04-10 | 2016-07-20 | 杨岭燕 | 一种用于妇产科中胎膜破裂诊断用的适配子及其试剂盒 |
Non-Patent Citations (2)
Title |
---|
宮川 伸ほか,"バイオ素材による創薬とDDS RNAアプタマーを用いた分子標的医薬の開発",Drug Delivery System,2008年,第23巻、第5号,p.534-543 |
秦野 雄ほか,"臨床セミナー これからの心不全バイオマーカー(第7回)接着因子(ICAM-1,VCAM-1,P-selectin)",Fluid management renaissance = フルイドマネジメントルネッサンス / 「Fluid management renaissance」編集委員会 編,2013年01月,第3巻, 第1号,p.67-73 |
Also Published As
Publication number | Publication date |
---|---|
CN112469828A (zh) | 2021-03-09 |
WO2020020947A1 (en) | 2020-01-30 |
CN112469828B (zh) | 2024-04-30 |
JP2021531020A (ja) | 2021-11-18 |
US11274308B2 (en) | 2022-03-15 |
EP3827082A1 (en) | 2021-06-02 |
US20210292762A1 (en) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7434276B2 (ja) | Icam-1アプタマー、その診断および治療用途 | |
US20220090080A1 (en) | Method for Generating Aptamers with Improved Off-Rates | |
US6613526B2 (en) | Systematic evolution of ligands by exponential enrichment: tissue selex | |
JP5684568B2 (ja) | 改善されたオフ速度(off−rate)を持つアプタマーを生成するための方法 | |
US20110143953A1 (en) | Synthetic Antibodies | |
Brodyagin et al. | Chemical approaches to discover the full potential of peptide nucleic acids in biomedical applications | |
Uhlig et al. | Alkynes as an eco-compatible “on-call” functionality orthogonal to biological conditions in water | |
BG106361A (bg) | Лиганди на нуклеинови киселини за тенасцин - с | |
JP2010085108A (ja) | 生体光イメージング用プローブ | |
WO2015117206A1 (en) | Improved aptamers | |
JP6041373B2 (ja) | TNF−αに結合するアプタマー分子 | |
US20220348923A1 (en) | Ca-ix aptamers and diagnostic and therapeutic uses thereof | |
US6743627B1 (en) | Using polyamide nucleic acid oligomers to engender a biological response | |
EP4148132A1 (en) | Novel nucleic acid ligand, and method for identifyng same | |
US10413621B2 (en) | Composition and methods for imaging cells | |
US20020108130A1 (en) | Extracellular drug-oligonucleotides chimeric molecules | |
US20030100519A1 (en) | Using polyamide nucleic acid oligomers to engender a biological response | |
US11613746B2 (en) | Methods for developing virus protein specific capture agents, capture agents, and methods of using the capture agents | |
WO2023068328A1 (ja) | 標的ペプチド分解誘導剤 | |
Gordon | Developing Methods for Discovering Non-Natural and pH Switching Aptamers | |
WO2023010036A1 (en) | Bc200 rna decoy compounds and methods of use for the treatment of autoimmune diseases, including lupus | |
WO2023211299A1 (en) | Dna aptamer having affinity for pd-l1 protein and its use, functional covalent complex and its use | |
US20110184042A1 (en) | RNA Aptamer Specifically Binding to Carcinoembryonic Antigen and Use thereof | |
JP2024046855A (ja) | インテグリンα7β1受容体に対する結合能を有するDNAアプタマー | |
JP2013236938A (ja) | 生体光イメージング用プローブ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220607 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230425 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230509 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230807 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240130 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240207 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7434276 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |